Ann: Cellmid News , page-9

There is a lot in this news.

= Evolis exceeding expectations to this point in time. The risk ATM maybe having enough stock to keep the shelves stocked . Oh dear . Stay tuned the Company says.

= HU91 funding partnership(s) "commenced discussions with corporate venture groups with the view to seek a strategic,
non-dilutive investment into this potentially highly
lucrative program." Suggests that the partner(s) will buy a stake in the program rather than the company. $500m banchmark valuation would be reduced by any
partnership arrangement. Given CDY's current market cap and resources OK, I agree with the strategy.

= Preclinical MK antibody testing are a must read. Derisks the science for several pipelines.

= Some nice new collaborations mentioned. Did I read Pfizer amongst them. Early days maybe but an excellent conference result!

Plenty of cash and more at the sidelines it seems. Read in context with the Boardroom Radio R&D rebate chat, and the response to the ASX I remain very very happy.

cheers